Litigation Details for Regeneron Pharmaceuticals, Inc v. Novartis Pharma AG (2d Cir. 2022)
✉ Email this page to a colleague
Regeneron Pharmaceuticals, Inc v. Novartis Pharma AG (2d Cir. 2022)
| Docket | ⤷ Try a Trial | Date Filed | 2022-03-01 |
| Court | Court of Appeals for the Second Circuit | Date Terminated | 2024-03-18 |
| Cause | Assigned To | ||
| Jury Demand | Referred To | ||
| Patents | 9,220,631 | ||
| Link to Docket | External link to docket | ||
Biologic Drugs cited in Regeneron Pharmaceuticals, Inc v. Novartis Pharma AG
The biologic drugs covered by the patent cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Details for Regeneron Pharmaceuticals, Inc v. Novartis Pharma AG (2d Cir. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2022-06-10 | 65 | effort, Novartis secured U.S. Patent No. 9,220,631 (the “’631 Patent”), which is directed to an anti-VEGF…proceedings. But Novartis obtained that patent only by defrauding the U.S. Patent and Trademark Office (“PTO”):…consumers, immunizing abuses of the patent system whenever the patent and market are coextensive. … collaboration culminated in the ’631 Patent. The ’631 Patent claims an anti-VEGF PFS, and specifically…that failed patent application were the very same attorneys who prosecuted the ’631 Patent application | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
